Through the 340B program, YNHH provides discharge prescriptions to 340B-eligible patients at a lower cost, which is particularly beneficial to indigent and self-pay patients. In addition, through its own pharmacy and a small network of contract pharmacies, YNHH is able to provide lower-cost medications to its large clinic population. The clinic receives more than 100,000 visits per year. Numerous chronic conditions are treated, such as cardiac disease, HIV, diabetes and hepatitis C. As a result of the 340B program, patients are better able to afford their prescribed medications and manage their chronic conditions.

Impact if the Program was Scaled Back:
If the 340B program was reduced, YNHH would struggle to provide newly discharged patients with a supply of medications. Patient discharges would be delayed in order to keep patients stable, resulting in a backlog of available inpatient beds. Clinic patients with chronic conditions may not be able to afford their medications, leading to poorer health and increased clinic/ED visits. In addition, oncology patients would have much higher copayments, which may prove cost-prohibitive, potentially resulting in a threat to access to appropriate care for their conditions.